24-Norursodeoxycholic acid reshapes immunometabolism in CD8(+) T cells and alleviates hepatic inflammation

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555 · see citing works

mTOR Signaling in Growth, Metabolism, and Disease.

Saxton, R., & Sabatini, D. (2017) · Cell · doi:10.1016/j.cell.2017.03.035 · Cited by 3,889 · see citing works

mTOR regulates memory CD8 T-cell differentiation

Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · see citing works

Fueling Immunity: Insights into Metabolism and Lymphocyte Function

Pearce, E. L., Poffenberger, M. C., Chang, C.-H., & Jones, R. G. (2013) · Science · doi:10.1126/science.1242454 · Cited by 1,363 · see citing works

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion

Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868 · see citing works

Primary sclerosing cholangitis – a comprehensive review

Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868 · see citing works

Immunoregulatory functions of mTOR inhibition

Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009) · Nature reviews. Immunology · doi:10.1038/nri2546 · Cited by 849 · see citing works

The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection

Maini, M. K., Boni, C., Lee, C. K., Larrubia, J. R., Reignat, S., Ogg, G. S., King, A. S., Herberg, J. A., Gilson, R. J. C., Alisa, A., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.8.1269 · Cited by 800 · see citing works

PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells

Finlay, D. K., Rosenzweig, E., Sinclair, L. V., Feijoo-Carnero, C., Hukelmann, J. L., Rolf, J., Panteleyev, A. A., Okkenhaug, K., & Cantrell, D. A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112607 · Cited by 596 · see citing works

Metabolic switching and fuel choice during T‐cell differentiation and memory development

van der Windt, G. J. W., & Pearce, E. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01150.x · Cited by 563 · see citing works

New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond

Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537 · see citing works

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

Fickert, P., Fuchsbichler, A., Wagner, M., Zollner, G., Kaser, A., Tilg, H., Krause, R. G. E., Lammert, F., Langner, C., Zatloukal, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.009 · Cited by 468 · see citing works

mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation

Pollizzi, K. N., Patel, C. H., Sun, I., Oh, M. H., Waickman, A. T., Wen, J., Delgoffe, G. M., & Powell, J. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77746 · Cited by 409 · see citing works

Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation

Tan, H., Yang, K., Li, Y., Shaw, T. I., Wang, Y., Blanco, D. B., Wang, X., Cho, J.-H., Wang, H., Rankin, S., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.010 · Cited by 372 · see citing works

24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice

Fickert, P., Wagner, M., Marschall, H., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O., Zatloukal, K., Liu, J., Waalkes, M. P., Cover, C., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.018 · Cited by 301 · see citing works

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.009 · Cited by 297 · see citing works

Effect of side-chain shortening on the physiologic properties of bile acids: Hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents

Yoon, Y. B., Hagey, L. R., Hofmann, A. F., Gurantz, D., Michelotti, E. L., & Steinbagh, J. H. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90859-0 · Cited by 248 · see citing works

T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay?

Zinkernagel, R. M., Haenseler, E., Leist, T., Cerny, A., Hengartner, H., & Althage, A. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.4.1075 · Cited by 208 · see citing works

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 −/− mice†‡§

Halilbasic, E., Fiorotto, R., Fickert, P., Marschall, H., Moustafa, T., Spirlı̀, C., Fuchsbichler, A., Gumhold, J., Silbert, D., Zatloukal, K., et al. (2009) · Hepatology · doi:10.1002/hep.22891 · Cited by 157 · see citing works

The immunobiology of mTOR in autoimmunity

Suto, T., & Karonitsch, T. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102373 · Cited by 149 · see citing works

Persistent Virus Infection despite Chronic Cytotoxic T-Lymphocyte Activation in Gamma Interferon-Deficient Mice Infected with Lymphocytic Choriomeningitis Virus

Bartholdy, C., Christensen, J. P., Wodarz, D., & Thomsen, A. R. (2000) · Journal of Virology · doi:10.1128/jvi.74.22.10304-10311.2000 · Cited by 136 · see citing works

Phosphatidic Acid Activates Mammalian Target of Rapamycin Complex 1 (mTORC1) Kinase by Displacing FK506 Binding Protein 38 (FKBP38) and Exerting an Allosteric Effect

Yoon, M., Sun, Y., Arauz, E. J., Jiang, Y., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.262816 · Cited by 134 · see citing works

Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function

Lercher, A., Bhattacharya, A., Popa, A., Caldera, M., Schlapansky, M. F., Baazim, H., Agerer, B., Gürtl, B., Kosack, L., Májek, P., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.10.014 · Cited by 120 · see citing works

Novel biotransformation and physiological properties of norursodeoxycholic acid in humans†‡

Hofmann, A. F., Zakko, S. F., Lira, M., Clerici, C., Hagey, L. R., Lambert, K. K., Steinbach, J. H., Schteingart, C. D., Olinga, P., & Groothuis, G. M. M. (2005) · Hepatology · doi:10.1002/hep.20943 · Cited by 110 · see citing works

Clonal Exhaustion as a Mechanism to Protect Against Severe Immunopathology and Death from an Overwhelming CD8 T Cell Response

Cornberg, M., Kenney, L. L., Chen, A. T., Waggoner, S. N., Kim, S.-K., Dienes, H. P., Welsh, R. M., & Selin, L. K. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00475 · Cited by 109 · see citing works

Loss of CD28 Expression by Liver-Infiltrating T Cells Contributes to Pathogenesis of Primary Sclerosing Cholangitis

Liaskou, E., Jeffery, L. E., Trivedi, P. J., Reynolds, G. M., Suresh, S., Bruns, T., Adams, D., Sansom, D. M., & Hirschfield, G. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.003 · Cited by 104 · see citing works

CD8+ T cells induce cachexia during chronic viral infection

Baazim, H., Schweiger, M., Moschinger, M., Xu, H. C., Scherer, T., Popa, A., Gallage, S., Ali, A., Khamina, K., Kosack, L., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0397-y · Cited by 89 · see citing works

Re-examining the Nature and Function of Self-Reactive T cells

Richards, D. M., Kyewski, B., & Feuerer, M. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.005 · Cited by 80 · see citing works

Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists

Webb, G. J., Rana, A. A., Hodson, J. A., Akhtar, M. Z., Ferguson, J., Neuberger, J., Vierling, J. M., & Hirschfield, G. M. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.09.062 · Cited by 61 · see citing works

Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice

Ravichandran, G., Neumann, K., Berkhout, L. K., Weidemann, S. A., Langeneckert, A. E., Schwinge, D., Poch, T., Huber, S., Schiller, B., Hess, L. U., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.023 · Cited by 56 · see citing works

Detailed Analysis of Intrahepatic CD8 T Cells in the Normal and Hepatitis C-Infected Liver Reveals Differences in Specific Populations of Memory Cells with Distinct Homing Phenotypes

Heydtmann, M., Hardie, D. L., Shields, P. L., Faint, J., Buckley, C. D., Campbell, J. J., Salmon, M., & Adams, D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.729 · Cited by 53 · see citing works

Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances

Ohradanova‐Repic, A., Machacek, C., Charvet, C., Lager, F., Roux, D. L., Platzer, R., Leksa, V., Mitulović, G., Burkard, T. R., Zlabinger, G. J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00852 · Cited by 52 · see citing works

Cellular Size as a Means of Tracking mTOR Activity and Cell Fate of CD4+ T Cells upon Antigen Recognition

Pollizzi, K. N., Waickman, A. T., Patel, C. H., Sun, I., & Powell, J. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121710 · Cited by 48 · see citing works

Enhancing immunity prevents virus‐induced T‐cell‐mediated immunopathology in B cell‐deficient mice

Straub, T., & Pircher, H. (2019) · European Journal of Immunology · doi:10.1002/eji.201847962 · Cited by 7 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis

Wang, J., Zhu, N., Su, L., Gao, Y., & Yang, R. (2023) · Cells · doi:10.3390/cells12050793 · Cited by 624 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

Bile acid metabolism and signalling in liver disease

Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 246 · see citing works

Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options

Grander, C., Grabherr, F., & Tilg, H. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad095 · Cited by 216 · see citing works

Effects of altered glycolysis levels on CD8+ T cell activation and function

Cao, J., Liao, S., Zeng, F., Liao, Q., Luo, G., & Zhou, Y. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05937-3 · Cited by 164 · see citing works

Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity

Su, L., Gao, Y., & Yang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127743 · Cited by 167 · see citing works

Bile acids and their receptors: modulators and therapeutic targets in liver inflammation

Bertolini, A., Fiorotto, R., & Strazzabosco, M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00935-7 · Cited by 142 · see citing works

Immunology of bile acids regulated receptors

Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 84 · see citing works

Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development

Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 83 · see citing works

Primary sclerosing cholangitis

Manns, M. P., Bergquist, A. M., Karlsen, T. H., Levy, C., Muir, A. J., Ponsioen, C. Y., Trauner, M., Wong, G. L., & Younossi, Z. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00600-x · Cited by 71 · see citing works

NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis

Huang, B., Lyu, Z., Qian, Q., Chen, Y., Zhang, J., Li, B., Li, Y., Liang, J., Liu, Q., Li, Y., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.014 · Cited by 60 · see citing works

Recent Advances in the Management of Primary Sclerosing Cholangitis

Assis, D. N., & Bowlus, C. L. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.004 · Cited by 55 · see citing works

Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases†

Nevens, F., Trauner, M. A., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 51 · see citing works

The history and future of bile acid therapies

Beuers, U. H., Bañales, J. M., Karpen, S. J., Keitel, V., Williamson, C., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.010 · Cited by 43 · see citing works

Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities

Gupta, V., Sehrawat, T. S., Pinzani, M., & Strazzabosco, M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.07.044 · Cited by 35 · see citing works

Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors

Wang, J., Zhu, N., Su, L., & Yang, R. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216582 · Cited by 32 · see citing works

Therapeutic modulation of the liver immune microenvironment

Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 31 · see citing works

The Roles of Gut Microbiota Metabolites in the Occurrence and Development of Colorectal Cancer: Multiple Insights for Potential Clinical Applications

Cheng, W., Li, F., & Yang, R. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.05.012 · Cited by 28 · see citing works

Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease

Trauner, M. A., Karpen, S. J., & Dawson, P. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001438 · Cited by 26 · see citing works

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape

Bhushan, S. R., Sohal, A., & Kowdley, K. V. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003174 · Cited by 29 · see citing works

24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T H 17 pathogenicity and transdifferentiation

Zhu, C., Boucheron, N., Al-Rubaye, O., Chung, B. K., Thorbjørnsen, L. W., Köcher, T., Schuster, M., Claudel, T., Halilbasic, E., Kunczer, V., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333297 · Cited by 25 · see citing works

L-Citrulline Supplementation Restrains Ferritinophagy-Mediated Ferroptosis to Alleviate Iron Overload-Induced Thymus Oxidative Damage and Immune Dysfunction

Ba, T., Zhao, D., Chen, Y., Zeng, C., Zhang, C., Niu, S., & Dai, H. (2022) · Nutrients · doi:10.3390/nu14214549 · Cited by 25 · see citing works

Cellular Interactions and Crosstalk Facilitating Biliary Fibrosis in Cholestasis

Ceci, L., Gaudio, E., & Kennedy, L. L. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.005 · Cited by 25 · see citing works

Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments

Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13191650 · Cited by 22 · see citing works

Exploring effects of gut microbiota on tertiary lymphoid structure formation for tumor immunotherapy

Liu, Y., Li, F., Wang, J., & Yang, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1518779 · Cited by 21 · see citing works

Macrophages in cholangiopathies

Bruneau, A., Guillot, A., & Tacke, F. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000814 · Cited by 18 · see citing works

Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis

Kellerer, M., Javed, S., Casar, C., Will, N., Berkhout, L. K., Schwinge, D., Krebs, C. F., Schramm, C., Neumann, K., & Tiegs, G. (2024) · Hepatology · doi:10.1097/hep.0000000000000830 · Cited by 17 · see citing works

Complex interplay between the immune system, metabolism, and epigenetic factors in autoimmune liver diseases

Xu, Y., Zhao, Z., Yan, E. P., Lian, Z., & Zhang, W. (2023) · Medicine Advances · doi:10.1002/med4.23 · Cited by 18 · see citing works

Bile acids attenuate hepatic inflammation during ischemia/reperfusion injury

Huang, K., Wang, C., Mei, B., Li, J., Ren, T., Zhan, H., Zhang, Y., Zhang, B., Lv, X., Zhang, Q., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101101 · Cited by 16 · see citing works

Targeting bile salt homeostasis in biliary diseases

Trampert, D. C., Kunst, R. F., & van de Graaf, S. F. J. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000997 · Cited by 11 · see citing works

The Role of Gut Microbiota in Neuromyelitis Optica Spectrum Disorder

Yao, S.-Q., Yang, X.-Y., Cen, L.-P., & Tan, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063179 · Cited by 11 · see citing works

Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice

Truong, J. K., Li, J., Li, Q., Pachura, K. J., Rao, A., Gumber, S., Fuchs, C. D., Feranchak, A. P., Karpen, S. J., Trauner, M. A., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.149360 · Cited by 11 · see citing works

Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies

Wang, W., Lian, H., Liang, Y., Ye, Y., Tam, P. K. H., & Chen, Y. (2024) · Cells · doi:10.3390/cells13231997 · Cited by 11 · see citing works

Immunobiology of bile and cholangiocytes

Yang, L., Leung, P. S. C., Zhang, W., Zhang, S., Liu, Z., Kurth, M. J., Patterson, A. D., Gershwin, M. E., & Song, J. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103376 · Cited by 10 · see citing works

24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ

Grander, C., Meyer, M., Steinacher, D., Claudel, T., Hausmann, B., Pjevac, P., Grabherr, F., Oberhuber, G., Grander, M., Brigo, N., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100872 · Cited by 9 · see citing works

Bile Acids and Bile Acid Metabolites in the Activation and Inhibition of Pyroptotic Cell Death, Influencing Inflammation

Avcioglu, S. Y., & Berkel, Ç. (2025) · Apmis · doi:10.1111/apm.70066 · Cited by 6 · see citing works

An update on novel pharmacological agents for primary sclerosing cholangitis

Gallo, C., Howardson, B. O., Cristoferi, L., Carbone, M., Gershwin, M. E., & Invernizzi, P. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2030707 · Cited by 6 · see citing works

Oleanolic acid alleviates ulcerative colitis by remodeling Th17 cells via targeting HSP90β-ODC1 pathway-mediated polyamine synthesis

Yuan, Y., Tian, Y., Zhao, Z., Yang, G., Wang, J., Zhu, F., Xue, G., Gao, F., Liu, Y., & Fan, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157441 · Cited by 6 · see citing works

Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview

Kasztelan‐Szczerbińska, B., Rycyk, A., Szczerbińska, A., & Cichoż‐Lach, H. (2023) · Nutrients · doi:10.3390/nu15030760 · Cited by 6 · see citing works

Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases

Hu, T., Tong, J., Yang, Y., Yuan, C., Zhang, J., & Wang, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1494248 · Cited by 3 · see citing works

Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis

Poch, T., Bahn, J., Casar, C., Krause, J., Evangelakos, I., Giladi, H., Kunzmann, L., Laschtowitz, A., Iuso, N., Schäfer, A.-M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101620 · Cited by 3 · see citing works

Bile acid therapy for primary biliary cholangitis: Pathogenetic validation

Reshetnyak, V. I., & Maev, I. V. (2024) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i1.101771 · Cited by 3 · see citing works

Taurochenodeoxycholic acid as a sensitive stratification marker for HBV-associated hepatic cirrhosis status has a hepatoprotective effect

Zeng, J., Wu, L., Xie, H., Liu, W., Shen, N., & Luo, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-16348-z · Cited by 2 · see citing works

Jun Ginger Extract Improves Cold‐Induced Asthma by Inhibiting Airway Inflammation via PI3K / AKT Pathway

Wang, X., Song, X., Ding, H., Liu, Z., Deng, F., Yan, H., & Yu, B. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.71249 · Cited by 1 · see citing works

Rapid quantification of bile acids in serum by LC-MS/MS and application to serum bile acid profile in voriconazole administered patients with invasive fungal infections

Yang, X., Qin, H., Ling, J., Dong, L., Jiang, Y., Zou, S., & Hu, N. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2625865 · Cited by 1 · see citing works

Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis

Pham, H. N., Pham, L., & Sato, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2362263 · Cited by 1 · see citing works

Safety, Tolerability, and Pharmacokinetics of NorUrsodeoxycholic Acid (Shilpa Medicare Limited, India) in Healthy Adults: Results From a Phase I Open‐Label Dose‐Escalation Study

Panuganti, V. K., Alluri, C. V., Dundigalla, M. R., Mohammad, J., Madala, P. K., & V., S. K. S. S. V. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/6613969 · Cited by 1 · see citing works

24-Nor-ursodeoxycholic acid counteracts T H 17/Treg imbalance and ameliorates intestinal inflammation by restricting glutaminolysis in differentiating T H 17 cellsPreprint

Zhu, C., Boucheron, N., Rîca, R., Stolz, V., Halilbasic, E., Claudel, T., Al-Rubaye, O., Lercher, A., Baumgartner, M., Sandner, L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.10.479975 · Cited by 1 · see citing works

24-Nor-ursodeoxycholic acid: a novel treatment targeting T-cell-mediated immune dysregulation in primary sclerosing cholangitis and beyond

Tan, L., & Wu, W. K. K. (2025) · Gut · doi:10.1136/gutjnl-2025-334966

Immunology of Autoimmune Liver Diseases

Kayani, K., Bozward, A. G., Davies, S. P., Jeyaraj, R., Asif, A., & Oo, Y. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00173-3

Crosstalk between CD8 + T cells and systemic bile acid metabolism controls LCMV-induced immunopathologyPreprint

Keszei, Z., Richter, F. C., Colaço, H. G., Baumgartner, M., Antonio-Herrera, L., Siller, M., Hofmann, A., Viczenczová, C., Baazim, H., Fuchs, C. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.17.670599

The conjugation-resistant bile acid norUDCA cures liver fibrosis but impairs systemic energy metabolismPreprint

Heeren, J., Evangelakos, I., Verkade, E., Kuipers, F., Rohde, J. S., Heine, M., Worthmann, A., Graute, S., Fuh, M. M., Gunasekaran, K., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8280795/v1

Die primär sklerosierende Cholangitis als cholestatische Lebererkrankung und Modellerkrankung einer gestörten Darm-Leber-Achse

Dignus, P., Albert, J., Hengstler, J. G., & Trautwein, C. (2026) · Die Gastroenterologie · doi:10.1007/s11377-025-00953-5

Immunpathogenese und Therapie der Primär Sklerosierenden Cholangitis

Zecher, B. F., & Schramm, C. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2730-4719

The conjugation-resistant bile acid norUDCA cures liver fibrosis but impairs systemic energy metabolism

Evangelakos, I., Verkade, E., Rohde, J. K., Zaufel, A., Vargek, M., Heine, M., Worthmann, A., Graute, S., Fuh, M. M., Gunasekaran, K., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102363

Primary sclerosing cholangitis: Time to rethink imaging criteria for early disease detection

Schramm, C., Poetter‐Lang, S., Halilbasic, E., Ba‐Ssalamah, A., Trauner, M., Bergquist, A., Ringe, K. I., Grigoriadis, A., & Lemoinne, S. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.009

Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review

Malakar, S., Sood, N., Giri, S., & Samanta, A. (2026) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.120122

Crosstalk between CD8+ T cells and systemic bile acid metabolism shapes antiviral immunity and immunopathology

Richter, F. C., Keszei, Z., Viczenczová, C., Baumgartner, M., Colaço, H. G., Siller, M., Holnsteiner, L., Baazim, H., Hofmann, A., Burrett, A., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.189882

Advances in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

Sandhu, S., & Goel, A. (2026) · Seminars in Liver Disease · doi:10.1055/a-2952-2261

Bile acid signaling in health and disease

Fan, Z., He, M., Liang, T., 张必利, Zhao, N., & Li, P. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00603-4

Crosstalk between gut microbiota-associated metabolites and adaptive immunity in cholecystitis: a conceptual mechanistic framework and potential therapeutic implications

Wang, X., Zhang, T., Ren, Z., & Ju, B. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1972466

From Structural Modification to Diverse Pharmacological Activities: Recent Advances and Future Perspectives of Bile Acids

Zhu, H., Chen, H., Gong, Q., Chen, Z., Zhang, C., Xu, J., & Wang, T. (2026) · Medicinal Research Reviews · doi:10.1002/med.70116

Gut Microbiota-Induced Metabolic Reprogramming of the Host Immune System

Roy, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-30306-6_7

PS-010-24-nor-ursodeoxycholic acid ameliorates inflammation by reshaping mTOR proteome and immunometabolism sensing programs in CD8 T-cells

Zhu, C., Boucheron, N., Müller, A. C., Májek, P., Fuchs, C. D., Baazim, H., Halilbasic, E., Stojaković, T., Bergthaler, A., Ellmeier, W., et al. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30016-7 · Cited by 1 · see citing works

Tissue CD14+CD8+T-cells reprogrammed by myeloid cells and modulated by LPS

Pallett, L., Swadling, L., Diniz, M., Maini, A. A., Schwabenland, M., Gasull, A. D., Davies, J., Kucykowicz, S., Skelton, J., Thomas, N., et al. (2023) · Nature · doi:10.1038/s41586-022-05645-6 · Cited by 68 · see citing works

CD8+ T-cells drive liver injury and hepatocellular carcinoma in chronic liver disease.

Endig, J., Buitrago, L. E., Marhenke, S., Saborowski, A., Schuett, J., Reisinger, F., Limbourg, F., Koenecke, C., Schreder, A., Geffers, R., et al. (2015) · PuSH - Publication Server of Helmholtz Zentrum München

Norursodeoxycholsäure moduliert die LPS-induzierte Entzündungsantwort in der Leber durch Interaktion mit dem NFκB Signalweg

Halilbasic, E., Claudel, T., Bachhofner, N., Kapusta, C., Fickert, P., & Trauner, M. A. (2012) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0032-1313835

Multi-omics integrated analysis reveals the therapeutic mechanism of 919 formula in metabolic dysfunction-associated steatotic liver disease.

Chen, Y., Lin, Z.-H., Niu, Y., Zheng, Q.-Q., Chen, M.-M., & Gao, P. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158839